Glioma Clinical Trials in San Antonio, Texas

4 studies are recruiting for glioma in San Antonio, Texas right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

  1. SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)

    This is a 3-part study. The purpose of Part 1 of the study is to evaluate the efficacy, safety, and pharmacokinetic (PK) characteristics of safusidenib in participants with recurrent/progressive IDH1-mutant World Health Organization (WHO) Grade 2 or Grade 3 glioma. The purpose of Part 2 will be to …

    Stage
    Phase 3
    Ages
    18 and older
    Site
    University of Texas Health Mays Cancer Center, San Antonio, Texas
    Locations
    61 in total
    Run by
    Nuvation Bio Inc.

    See if you can join NCT05303519 on ClinicalTrials.gov

  2. ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the ACTION Study)

    This is a randomized, double-blind, placebo-controlled, parallel-group, international, Phase 3 study in patients with newly diagnosed H3 K27M-mutant diffuse glioma to assess whether treatment with dordaviprone (ONC201) following frontline radiotherapy will extend overall survival and progression-fr…

    Stage
    Phase 3
    Ages
    Any age
    Site
    University of Texas - San Antonio - Health Science Center, San Antonio, Texas
    Locations
    162 in total
    Run by
    Jazz Pharmaceuticals

    See if you can join NCT05580562 on ClinicalTrials.gov

  3. Safety & Efficacy/Tolerability of Rhenium-186 NanoLiposomes (186RNL) for Patients Who Received a Prior 186RNL Treatment

    This is an open-label, multicenter, Phase 1 study to establish the safety and efficacy/tolerability of a single dose of 186RNL by the intraventricular route (via intraventricular catheter) for recurrence glioma in patients who received a prior treatment of 186RNL.

    Stage
    Phase 1
    Ages
    18 and older
    Site
    The Cancer Therapy and Research Center at UTHSCSA, San Antonio, Texas
    Run by
    Cerenome

    See if you can join NCT05460507 on ClinicalTrials.gov

  4. Maximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes in Recurrent Glioma (ReSPECT)

    This is a multi-center, sequential cohort, open-label, volume and dose escalation study of the safety, tolerability, and distribution of 186RNL given by convection enhanced delivery to patients with recurrent or progressive malignant glioma after standard surgical, radiation, and/or chemotherapy tr…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    The Cancer Therapy and Research Center at UTHSCSA, San Antonio, Texas
    Locations
    3 in total
    Run by
    Cerenome

    See if you can join NCT01906385 on ClinicalTrials.gov

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.